Drawing for CEPTELA

USPTO serial 77174302

CEPTELA

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
—
Law office
INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CEPTELA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew Pater

MATTHEW PATER PFIZER INC.150 E 42ND STNEW YORK, NY 10017-5612UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of liver, cardiovascular, central nervous system, endocrine, gastrointestinal, gynecological, hematologic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncological, ophthalmological, psychiatric, respiratory, sleep, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of allergies, erectile dysfunction, sexual dysfunction, obesity, pain, and HIV/AIDS; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 4, 2007MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Jun 4, 2007ABN1ABANDONMENT - EXPRESS MAILED—
Jun 3, 2007EXARTEAS EXPRESS ABANDONMENT RECEIVED—
May 10, 2007NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance